This is a news story, published by Investor's Business Daily, that relates primarily to David Risinger news.
For more David Risinger news, you can click here:
more David Risinger newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Investor's Business Daily, you can click here:
more news from Investor's Business DailyOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
AbbVie stock. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Medical Stock news, Loss Drug Market news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
AbbVieInvestor's Business Daily
•
80% Informative
AbbVie 's drug, emraclidine, failed in two final-phase studies of patients with schizophrenia.
Leerink Partners analyst David Risinger says there's still a lot to like about the company.
He says the Cerevel takeover could eventually yield promising drugs in the coming years .
Risinger : "We believe investors can take advantage of the emracridine setback and election-related downdraft to purchase shares in this high-quality company".
VR Score
85
Informative language
92
Neutral language
48
Article tone
formal
Language
English
Language complexity
44
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
4
Source diversity
3
Affiliate links
no affiliate links